Competitive Comparison of Pieris Pharmaceuticals's Profitability Rank
For the Biotechnology subindustry, Pieris Pharmaceuticals's Profitability Rank, along with its competitors' market caps and Profitability Rank data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pieris Pharmaceuticals's Profitability Rank Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Pieris Pharmaceuticals's Profitability Rank distribution charts can be found below:
* The bar in red indicates where Pieris Pharmaceuticals's Profitability Rank falls into.
Pieris Pharmaceuticals Profitability Rank Calculation
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.
Pieris Pharmaceuticals has the Profitability Rank of 2. It has had trouble to make a profit.
Profitability Rank is not directly related to the Financial Strength. But if a company is consistently profitable, its financial strength will be stronger.
Profitability Rank is based on these factors:
1. Operating Margin %
Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.
Pieris Pharmaceuticals's Operating Margin % for the quarter that ended in Dec. 2023 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
2. Piotroski F-Score
Warning Sign:
Piotroski F-Score of 3 is low, which usually implies poor business operation.
The zones of discrimination were as such:
Good or high score = 8 or 9
Bad or low score = 0 or 1
Pieris Pharmaceuticals has an F-score of 3. It is a bad or low score, which usually implies poor business operation.
3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.
Good Sign:
Pieris Pharmaceuticals Inc operating margin is expanding. Margin expansion is usually a good sign.
4. Consistency of the profitability
5. Predictability Rank
Pieris Pharmaceuticals (Pieris Pharmaceuticals) Business Description
Traded in Other Exchanges
Address
225 Franklin Street, 26th Floor, Boston, MA, USA, 02110
Pieris Pharmaceuticals Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of the Anticalin class of biotherapeutics. Anticalin proteins are engineered versions of lipocalins, human proteins that naturally bind, store and transport a wide spectrum of molecules. The company with the help of technology creates differentiated drugs such as PRS-080, PRS-060, and PRS-332 that can help patients suffering from cancer, severe asthma, anemia, and other medical conditions with a high unmet medical need. Geographically, all the operation of the firm functions through the region of the United States.
Executives
| Ann Barbier |
director |
255 STATE STREET, C/O PIERIS PHARMACEUTICALS,INC., BOSTON MA 02109 |
| Peter A Kiener |
director |
40 GUEST STREET, BOSTON MA 02135 |
| Maya R. Said |
director |
C/O PIERIS PHARMACEUTICALS, INC., 255 STATE STREET, 9TH FLOOR, BOSTON MA 02109 |
| Matthew L Sherman |
director |
C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET, WALTHAM MA 02451 |
| Christopher P Kiritsy |
director |
|
| Bvf I Gp Llc |
10 percent owner |
44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104 |
| Bvf Ii Gp Llc |
other: See Explanation of Responses |
44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104 |
| Bvf Gp Holdings Llc |
10 percent owner |
44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104 |
| Shane Olwill |
officer: Chief Development Officer |
C/O PIERIS PHARMACEUTICALS, INC., 255 STATE STREET, 9TH FLOOR, BOSTON MA 02109 |
| Ahmed Mousa |
officer: Chief Business Officer |
255 STATE STREET, 9TH FLOOR, C/O PIERIS PHARMACEUTICALS, INC., BOSTON MA 02109 |
| Hitto Kaufmann |
officer: Chief Scientific Officer |
C/O PIERIS PHARMACEUTICALS, INC., 255 STATE STREET, 9TH FLOOR, BOSTON MA 02109 |
| Thomas Bures |
officer: Chief Financial Officer |
C/O PIERIS PHARMACEUTICALS, INC., 255 STATE STREET, 9TH FLOOR, BOSTON MA 02109 |
| Tim Demuth |
officer: Chief Medical Officer |
C/O PIERIS PHARMACEUTICALS, INC., 255 STATE STREET, 9TH FLOOR, BOSTON MA 02109 |
| Aquilo Capital Management, Llc |
10 percent owner |
ONE LETTERMAN DRIVE, SUITE D4900, BUILDING D, SAN FRANCISCO CA 94129 |
| Biotechnology Value Fund L P |
other: See Explanation of Responses |
44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104 |
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
PIRS has been successfully added to your